Episode 60
Biotech Hangout
00:00
The FTC's Decision to Block Amgen's Acquisition of Schmidt Cap Biotech
Horizon stock was down and it sounds very bad but overall, and I can't wait to hear others, we're definitely not freaking out. We do think that the decision by FTC to try to litigate this or block it is far reaching and has nothing to do with traditional rules and regulations about monopolies and consumer harm. And then three, you know, as much as Amgen and Horizon both said that there are committed to not doing that,. However, you hold them to that, we just think that's going to be a very difficult case.
Transcript
Play full episode
